The invention relates to HPK1 inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: where A, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.16, R.sub.17, X.sub.1, X.sub.2, X.sub.3, X.sub.4, m, and n are described herein. ##STR00001##

The invention relates to HPK1 inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: where A, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.16, R.sub.17, X.sub.1, X.sub.2, X.sub.3, X.sub.4, m, and n are described herein. ##STR00001##

An organic light emitting element produced by using a light emitting composition that contains both a first compound having a PBHT value more than 0.730 and a second compound having ES1 lower than that of the first compound and AEsT less than 0.20 eV is excellent in durability. ES1 is the lowest excited singlet energy level, AEsT is the difference between the lowest excited singlet energy level and the lowest excited triplet energy level.

A fluorescent dye, as well as a preparation method and uses thereof, wherein the fluorescent dye is sensitive and specific to viscosity and has low background fluorescence; it can also be used as a fluorescent activated and lighted probe used for fluorescent labeling, quantification or monitoring of protein, enzymes or nucleic acid.

Dye and compositions to monitor the multistep protein aggregation process in both test tubes and live cells are provided. These dyes can detect misfolded protein oligomers and distinguish insoluble protein aggregates from misfolded oligomers. Applications of these dyes include measuring kinetics of protein aggregation, monitoring aggregation of specific proteins in intact live cells, monitoring aggregation of cellular proteome in intact live cells, and tracking the time course of protein aggregation in cells under stress conditions.

A fused tricyclic compound and use thereof as a medicament, in particular as a medicament for the treatment and/or prevention of hepatitis B. Specifically, a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each variate is as defined in specification. The compound also includes a Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof as a medicament, especially as a medicament for the treatment and/or prevention of hepatitis B. ##STR00001##

Compounds having a structure of formula (I), including stereoisomers and pharmaceutically acceptable salts and solvates thereof: ##STR00001##
wherein R.sub.1 is as defined herein. Such compounds are inhibitors of the vesicular monoamine transporter 2 (VMAT2) and have utility for treating, for example, hyperkinetic disorders. Also disclosed are compositions containing these compounds in combination with a pharmaceutically acceptable carrier or diluent, as well as methods relating to the use in a subject in need thereof.

Compounds having a structure of formula (I), including stereoisomers and pharmaceutically acceptable salts and solvates thereof: ##STR00001##
wherein R.sub.1 is as defined herein. Such compounds are inhibitors of the vesicular monoamine transporter 2 (VMAT2) and have utility for treating, for example, hyperkinetic disorders. Also disclosed are compositions containing these compounds in combination with a pharmaceutically acceptable carrier or diluent, as well as methods relating to the use in a subject in need thereof.

Provided are four crystal forms, A, B, C and D, of demethyleneberberine hydrochloride, and a preparation method therefor, and further provided are X-ray powder diffraction characteristic absorption peaks, infrared absorption peaks and DSC spectra of the four crystal forms. The X-ray powder diffraction characteristic diffraction peaks of the crystal forms are at about 8.205, 8.805, 10.817, 14.835, 15.479, 16.668, 17.492, 18.529, 20.656, 21.536, 23.538, 25.657, 26.192, and 28.808. A preparation method for the four crystal forms of the demethyleneberberine hydrochloride is also involved. The preparation method has a simple process, a high yield and a low cost; and has a high product purity and a stable quality.

The present invention provides a luminescent film containing at least a phosphorescent compound and a fluorescent compound, wherein the convolution integral value J of the emission spectrum of the phosphorescent compound and the absorption spectrum of the fluorescent compound satisfies equation (1), the light emission from the fluorescent compound accounts for at least 90% of the emission spectrum of the luminescent film, and the absolute photoluminescence quantum efficiency (PLQE) of the luminescent film is represented by equation (2). Equation (1): J1.510.sup.14, Equation (2): PLQE (a film composed of a phosphorescent compound and a host compound)0.9PLQE (a film containing a phosphorescent compound and a fluorescent compound) [The lowest triplet excited state of the host compound is higher than the lowest triplet excited state of the phosphorescent compound, and does not suppress the luminescent property of the phosphorescent compound.]